Company Update (NASDAQ:INO): Inovio Pharmaceuticals to Present at Alliance Regenerative Medicine’s 2015 Regen Med Investor Day

Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that Chief Operating Officer, Dr.  Niranjan Sardesai, will present at the 3rd Annual Regen Med Investor Day to be held Wednesday, March 25, 2015 at the Metropolitan Club in New York City.

Dr. Sardesai's presentation will begin at 4:05 PM ET. A live-streaming webcast of all panels and company presentations, including Dr. Sardesai's, will be available at: The live and archived version of the event (to be made available upon completion of the conference) will also be available through the "Webcast" tab on Inovio's home page at

Organized by the Alliance for Regenerative Medicine and co-hosted by Piper Jaffray, the Regen Med Investor Day provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The program includes clinical and commercial experts who will address specific questions regarding the outlook for these products as well as offer insight into how advanced therapies could impact the standard of care in key therapeutic areas. In addition to presentations by more than 30 companies from across the globe, this event includes interactive panels featuring research analysts covering the space, key clinical opinion leaders, and top company CEOs(Original Source)

Shares of Inovio closed yesterday at $8.38. INO has a 1-year high of $13.04 and a 1-year low of $6.33. The stock's 50-day moving average is $7.48 and it's 200-day moving average is $9.38.

On the ratings front, Inovio (NASDAQ:INO) has been the subject of a number of recent research reports. In a report issued on March 16, Brean Murray Carret analyst Jonathan Aschoff reiterated a Buy rating on INO, with a price target of $20, which implies an upside of 138.7% from current levels. Separately, on March 12, H.C. Wainwright's Yi Chen initiated coverage with a Buy rating on the stock and has a price target of $17.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jonathan Aschoff and Yi Chen has a total average return of 18.4% and -1.4% respectively. Aschoff has a success rate of 65.1% and is ranked 58 out of 3535 while Chen has a success rate of 50.0% and is ranked 2739

Inovio Pharmaceuticals, Inc. is a biomedical company, engaged in the development of next-generation vaccines to prevent or treat cancers and chronic infectious diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts